#4 - Johnson & Johnson (NYSE:JNJ)
The final defensive stock on this list is Johnson & Johnson (NYSE:JNJ). As with many sectors, there are several attractive options in the pharmaceutical space. Some people may prefer Pfizer (NYSE:PFE), I’ll give the nod to JNJ because it offers exposure to both the pharmaceutical and consumer essentials space.
But that’s also why JNJ may not be a long-term play. The stock is showing tepid growth this year after the company announced it was going to spin off its consumer products division into a separate company. This is projected to happen in 2023. However, in the meantime, the company continues to generate consistent FCF that was $19.75 billion in 2021, down just a shade from the over $20 billion it generated in 2021.
And that growth is reflected in the company’s dividend which Johnson & Johnson just increased for the 61st consecutive year. This will keep JNJ in the exclusive group of stocks known as Dividend Kings.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
More- Current Price
- $153.64
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $170.67 (11.1% Upside)
